Although advancements in breast cancer detection and treatment have greatly improved patient outcomes, relapse from the disease is still a leading cause of cancer-related death in women. Recurrent breast tumors typically originate from a subpopulation of cancer cells that survive therapeutic interventions, and they are difficult to identify prior to relapse because they escape cancer therapy through adaptations that help them behave like normal cells.
In a study published this week in the JCI, a research team led by Martin Jechlinger at the European Molecular Biology Laboratory in Heidelberg, Germany examined gene transcription profiles and metabolism pathways in human breast cancer tumors and in mouse models of breast cancer. They discovered that residual tumor cells display alterations in gene transcription and metabolism that affect how the cells synthesize and store fats. Changes in fat metabolism were coupled to increases in oxidative stress and DNA damage, suggesting that residual cancer cells rely on these metabolic adaptations to acquire the mutations that trigger cancer relapse.
The researchers then examined pre- and post-treatment biopsies from breast cancer patients and, consistent with their previous findings, they discovered that post-treatment cells exhibited alterations in fat metabolism pathways. These findings provide important insights into the potential of targeting metabolic pathways in residual breast cancer cells as a strategy to prevent relapse.
###
TITLE: Metabolic Shifts in Residual Breast Cancer Drive Tumor Recurrence
AUTHOR CONTACT:
Martin Jechlinger
EMBL Heidelberg
martin.jechlinger@embl.de
View this article at: http://www.jci.org/articles/view/89914?key=67eb30dbc00eb1050f01
Journal
Journal of Clinical Investigation